HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER
Clinical trials for HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER trials appear
Sign up with your email to follow new studies for HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New PARP1 inhibitor IMP1734 enters human trials for advanced cancers
Disease control Recruiting nowThis study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…
Matched conditions: HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to extend remission in ovarian cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…
Matched conditions: HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Radioactive 'Bullets' aim to stop ovarian cancer spread in new trial
Disease control Recruiting nowThis study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either stand…
Matched conditions: HIGH-GRADE ENDOMETRIOID EPITHELIAL OVARIAN CANCER
Phase: PHASE2 • Sponsor: Oncoinvent Solutions AS • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC